TP53 and acute myeloid leukemia: Mutations of TP53 in AML are leukemogenic drivers and are of prognostic importance because they are often associated with drug resistance and poor outcomes (Rucker et al., 2012; Dohner et al., 2017; Tallman et al., 2019).